NCT04439318View on ClinicalTrials.gov

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 25, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2025

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma

Interventions

DRUG

Trametinib Dimethyl Sulfoxide

Given PO

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH